In
Inhibrx (Sanofi)
La Jolla CAFounded 2010150 employees
Private CapbiotechAcquiredOncologyRare Disease
Platform: BiTE INBRX-101
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Pexaderotide | INH-6995 | Phase 1/2 | 1 | APOC3 | WilmsObesity | ||
| INH-5545 | INH-5545 | Phase 3 | 3 | CD19 | CMLMelanoma | ||
| INH-3643 | INH-3643 | NDA/BLA | 1 | CD20 | AngelmanWM | ||
| INH-2936 | INH-2936 | Phase 2 | 2 | PD-L1 | PompeHCC |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (7)